Eagle Pharmaceuticals (EGRX) Tops Q1 EPS by 33c; Offers FY23 EPS Guidance

Eagle Pharmaceuticals (NASDAQ: EGRX) reported Q1 EPS of $1.26, $0.33 better than the analyst estimate of $0.93. Revenue for the quarter came in at $66.3 million versus the consensus estimate of $63.29 million.

GUIDANCE:

Eagle Pharmaceuticals sees FY2023 EPS of $4.20-$4.53, versus the consensus of $4.21.

For earnings history and earnings-related data on Eagle Pharmaceuticals (EGRX) click here.

You May Also Be Interested In

• uCloudlink Group Inc. (UCL) Misses Q2 EPS by 1c ; Offers Guidance
• Fabrinet (FN) Tops Q4 EPS by 29c, Beats on Revenue; Offers Guidance
• BofA Securities Reiterates Buy Rating on NVIDIA (NVDA)